AVANIR Pharmaceuticals's total inventories for the quarter that ended in Sep. 2014 was €0.62 Mil. AVANIR Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2014 to the quarter that ended in Sep. 2014 was €0.56 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. AVANIR Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2014 was €1.02.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
AVANIR Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2014 was -1.14.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
AVANIR Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2014 was 0.02.
AVANIR Pharmaceuticals Total Inventories Historical Data
The historical data trend for AVANIR Pharmaceuticals's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVANIR Pharmaceuticals Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
AVANIR Pharmaceuticals (FRA:AV2B) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
AVANIR Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2014 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
AVANIR Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
AVANIR Pharmaceuticals Total Inventories Related Terms
Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
AVANIR Pharmaceuticals (FRA:AV2B) Business Description
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AV2B has been successfully added to your 